So high-risk in myeloma is certainly an important topic because while the majority of myeloma patients are responding to treatment easily and having a fantastic outcome with the most recent quadruplets, there is still a subset of patients around a range of 15 to 20%, those patients have a high-risk future. Some of them are recognized at diagnosis, which is reflected by, for instance, by FISH...
So high-risk in myeloma is certainly an important topic because while the majority of myeloma patients are responding to treatment easily and having a fantastic outcome with the most recent quadruplets, there is still a subset of patients around a range of 15 to 20%, those patients have a high-risk future. Some of them are recognized at diagnosis, which is reflected by, for instance, by FISH. And in some reference centers with the gene expression profiling, that is also possible to demonstrate that. But despite all these genetic investigations, there are some subgroup of patients who, although they look like standard, they either may be refractory to the best regimen or may become refractory soon after the first induction or after the transplant. So this is a heterogeneous group of patients. They are all under the title of high risk. And how to approach this type of patients is a topic of interest and we are trying to recognize such cases ahead of time to allow them the best regimen not maybe in the first run but in the second run so that they can achieve deep and durable response.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.